Mergers & Acquisitions
By The Online Investor Staff, updated Wed., Mar. 3, 9:51 PM
| This Slide: #100 of 100 |
Slide #100. Exact Sciences Corp. — Ashion Analytics, LLC
Acquirer:
Exact Sciences Corp. (NASDAQ:EXAS)
Acquiree:
Ashion Analytics, LLC
Details:
Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Ashion is a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona with the genomics testing capabilities necessary to address the increasingly complex needs of clinical, academic, and biopharma customers focused on precision cancer treatments. The team at Ashion will help accelerate the development of Exact Sciences' precision oncology portfolio, including minimal residual disease (MRD) and other sequencing-based tests.
Exact Sciences is a cancer diagnostics company. Co. has developed several brands in cancer screening and diagnostics, including Cologuard and Oncotype DX. Co. has developed a non-invasive screening test called Cologuard® to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co. is also working on the development of additional tests for other types of cancer. Co. is also focusing its research and development efforts on building a pipeline of potential future products and services with a focus on blood-based tests. Co. is advancing liquid biopsy through biomarker discovery and validation in tissue, blood and other fluids.
EXAS SEC Filing Email Alerts Service
Open the EXAS Page at The Online Investor »
|
|||||||||||||||||||||
Open the EXAS Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Strong Buy (3.71 out of 4) 70th percentile
(ranked higher than approx. 70% of all stocks covered)
Analysts' Target Price: EXAS Stock Forecast Based on Zacks ABR data; powered by Xignite |
